白细胞介素-34在体外和体内抑制乙型肝炎病毒复制

StephenW

PLoS One. 2017 Jun 14;12(6):e0179605. doi: 10.1371/journal.pone.0179605. eCollection  2017.
Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo.Cheng ST1, Tang H1, Ren JH1, Chen X2, Huang AL1,3, Chen J1.
Author information
1Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.2Department of Clinical Laboratory, Zhuzhou Central Hospital, Zhuzhou, China.3Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Zhejiang, China.

AbstractBACKGROUND: The hepatitis B virus (HBV) infection could activate the immune system and induce extensive inflammatory response. As the most important inflammatory factor, interleukins are critical for anti-viral immunity. Here we investigated whether interleukin-34 (IL-34) play a role in HBV infection.
METHODOLOGY/PRINCIPAL FINDINGS: In this study, we first found that both serum IL-34 and IL-34 mRNA in PBMCs in chronic HBV patients was significantly decreased compared to the healthy controls. Furthermore, both IL-34 protein and mRNA levels were declined hepatoma cells expressing HBV. In addition, the clinical parameters analysis found that serum IL-34 was significantly associated with HBV DNA (P = 0.0066), ALT (P = 0.0327), AST (P = 0.0435), TB (P = 0.0406), DB (P = 0.0368) and AFP (P = 0.0225). Correlation analysis also found that serum IL-34 negatively correlated with HBV DNA copies, ALT and AST. In vitro studies found that IL-34 treatment in HepAD38 and HepG2.2.15 cells markedly inhibited HBV DNA, total RNA, 3.5kb mRNA and HBc protein. In vivo studies further demonstrated IL-34 treatment in HBV transgenic mice exhibited greater inhibition on HBV DNA, total RNA, 3.5kb mRNA and HBc protein, suggesting the effect to IL-34 on HBV is likely due to host innate or adaptive immune response.
CONCLUSIONS/SIGNIFICANCE: Our study identified a novel interleukin, IL-34, which has anti-viral activity in HBV replication in hepatocytes in vitro and in vivo. These data suggest a rationale for the use of IL-34 in the HBV treatment.


PMID:28614380DOI:10.1371/journal.pone.0179605

• 
  


• 
  

StephenW

PLoS One。 2017年6月14日; 12（6）：e0179605。 doi：10.1371 / journal.pone.0179605。 eCollection 2017。
白细胞介素-34在体外和体内抑制乙型肝炎病毒复制。
程ST1，唐H1，任JH1，陈X2，黄AL1,3，陈杰1。
作者信息

1
    重庆医科大学第二附属医院传染病病毒性肝炎病毒感染病分子生物学重点实验室（教育部）重庆医科大学重庆医科大学第二附属医院感染病科分子生物学重点实验室。
2
    中国株洲市株洲中心医院临床实验室。
3
    浙江大学传染病诊断与治疗合作创新中心。

抽象
背景：

乙型肝炎病毒（HBV）感染可激活免疫系统并诱发广泛的炎症反应。作为最重要的炎症因子，白细胞介素对于抗病毒免疫是至关重要的。在这里我们调查白细胞介素-34（IL-34）是否在HBV感染中发挥作用。
方法/主要发现：

在本研究中，我们首先发现，与健康对照组相比，慢性HBV患者PBMCs中的血清IL-34和IL-34 mRNA均显着降低。此外，IL-34蛋白和mRNA水平均下降，肝细胞表达HBV。另外临床参数分析发现血清IL-34与HBV DNA（P = 0.0066），ALT（P = 0.0327），AST（P = 0.0435），TB（P = 0.0406），DB（P = 0.0368）和AFP（P = 0.0225）。相关分析也发现血清IL-34与HBV DNA拷贝，ALT和AST呈负相关。体外研究发现，HepAD38和HepG2.2.15细胞中的IL-34处理显着抑制HBV DNA，总RNA，3.5kb mRNA和HBc蛋白。体内研究进一步证实，HBV转基因小鼠的IL-34治疗对HBV DNA，总RNA，3.5kb mRNA和HBc蛋白表现出更大的抑制作用，表明对HBV的IL-34的作用可能是由于宿主先天性或适应性免疫应答。
结论/意义：

我们的研究确定了一种新型白细胞介素IL-34，其在肝细胞体外和体内的HBV复制中具有抗病毒活性。这些数据表明在HBV治疗中使用IL-34的理由。

结论：
    28614380
DOI：
    10.1371 / journal.pone.0179605

StephenW

http://journals.plos.org/plosone ... ournal.pone.0179605

kite2002005

新版核苷吗

StephenW

回复 kite2002005 的帖子

不是，只是基础研究.